

Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Effectiveness and Value

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its review of disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis. ICER has invited input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- AbbVie, Inc.
- Aetna, Inc.
- American Academy of Neurology
- Anthem, Inc.
- Bayer AG
- Biogen Inc.
- Blue Shield of California
- California Department of Health Care Services
- Cigna, Inc.
- EMD Serono, Inc.
- Genentech, Inc. (Roche Group)
- Health Net, Inc.
- Humana, Inc.
- MS Coalition (member organizations listed below)
 - Accelerated Cure Project for Multiple Sclerosis
 - Consortium of Multiple Sclerosis Centers
 - Can Do MS
 - International Organization of Multiple Sclerosis Nurses
 - Multiple Sclerosis Association of America
 - Multiple Sclerosis Foundation
 - National Multiple Sclerosis Society

- United Spinal Association
- MS Views & News
- Novartis AG
- PatientsLikeMe
- Premera Blue Cross
- Sanofi Genzyme, Inc.
- Teva Neuroscience, Inc.
- UnitedHealthcare Services, Inc.